C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...
Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback